Kornimate/medical-research-clean huggingface dataset:
biopsychosocial factors in resistance exercise in individuals with knee pain

Conditions: Knee Pain

Summary: the purpose of this research is to examine changes in pain sensitivity during high fatigue exercise, low fatigue exercise, and no treatment in individuals who are currently experiencing knee pain. dosing dynamic resistance exercise intensity based on fatigue level is a novel, clinically feasible method. dynamic resistance exercise at a high intensity (75% 1 repetition maximum (rm)) produces significant hypoalgesia at local sites compared to no treatment; however, dosing intensity based on 1rm can be challenging to implement in the clinical setting. fatiguing endurance tasks produce local and systemic reductions in pressure pain threshold with low intensity isometric exercise completed until failure resulting in the largest exercise induced hypoalgesia effects. fatigue may be an important mediator in pain response to exercise.


Eligibility criteria:
inclusion criteria: * experiencing knee pain symptom intensity rated as 3/10 or higher in the past 24 hours exclusion criteria: * non-english speaking * history of knee surgery or fracture within the past 6 months * history of quadriceps tendon rupture * history of a chronic pain condition, such as fibromyalgia * systemic medical conditions that affect sensation, such as uncontrolled diabetes or neurological conditions * blood clotting disorder, such as hemophilia * known presence of cardiovascular, pulmonary, or metabolic disease * current use of tobacco products * contraindication to the application of ice, including blood pressure over 140/90 mmhg, -conditions that cause hives or blood in urine when exposed to cold, and any reductions in blood flow to arms or legs. * not physically ready to exercise without a medical exam as indicated by the physical activity readiness questionnaire + (par-q+) * pain during active knee range of motion 0-90 degrees (examined during screening) * pregnant * unable to attend 4 sessions
dc-cik immunotherapy plus chemotherapy vs chemotherapy alone in the adjuvant treatment of stage iii colorectal cancer

Conditions: Colorectal Cancer

Summary: stage iii colorectal cancer constitutes more than half of the colorectal patients, and the prognosis does not improve much recently although varies of adjuvant drugs have been tried. dc-cik immunotherapy has been proved to improve survival in cancer patients, but its role in stage iii colorectal cancer patients stains unclear. the investigators study will focus on the efficacy and safety of dc-cik immunotherapy plus chemotherapy in the adjuvant treatment of stage iii colorectal cancer, compared with chemotherapy alone.


Eligibility criteria:
inclusion criteria: * stage iii colon cancer * undergone complete resection of primary tumor * completed standard adjuvant chemotherapy * ecog performancer status 0-2 * adequate hematologic, hepatic and renal functions exclusion criteria: * hiv positive or other immunodeficiency disease * uncontrolled hypertension * history of recent cancers in the past 5 years * patients with previous or concurrent malignancy or any anti-cancer therapy * patients who were allergic to platinum drugs or fluorouracil * pregnant patients
study of pulse pressure during tilttable and erigo® in adult patients with acquired brain injury

Conditions: Brain Injuries; Hypotension, Orthostatic; Syncope

Summary: the purpose of this study is to determine if the pulse pressure changes are different whether patients are training in a traditional tilt table as compared to a robotic assisted tilt table, which induces leg movement.

the trial takes place in a non private hospital in denmark. patients are recruited from two wards treating patients with severe brain injury, and all patients admitted in the study period are considered in regards to inclusion or exclusion. patients are included via closest relatives accept, and the patients gp(general practitioner). any adverse effect or event will be reported to the local ethics committee. all data will be collected simultaneously with the interventions. some data will be directly recorded via monitor output, and some data will be directly inputted in epidata, while trial takes place. sample size has been calculated to be between 10 and 60 individuals depending on the actual difference. beyond 60 included individuals the clinical relevance of a statistical significant result is no longer apparent. if any individual variables are noncomplete, an analysis of the subjects with missing data, will be undertaken. the statistical analyses planned follows the general crossover design using an approach considering 2 treatment and 2 periods. patients are cluster randomized in clusters of 4, to be treated with one or the other intervention first. intervention a: traditional tilt table. measurements at 0 degrees 30 deg. 60. deg. and at return to 0 deg. intervention b: erigo® tilttable, with measurements as in intervention a. during the intervention the step frequency of the erigo® i set at 48 steps/min. between the two periods a wash out period of at least ½ hour and maximum 2 hours are planned. primary outcome is derived from noninvasive bp measurements.

Eligibility criteria:
inclusion criteria: * already being treated with traditional tilttable and must be able to benefit from erigo® treatment from a clinicians view * acquired brain injury as primary diagnose * must have rancho los amigo scale score of minimum 1 to maximum 6 on the day of inclusion exclusion criteria: * not on mechanical ventilation * new cerebral, cardiological or other medical problems/emergencies between the 2 interventions * change in cardiac medications between interventions * patient must not have independent gait function immediately before trial * must not have efa(early functional abilities) part score \> 4 in the section "standing", assessed by the treating physiotherapist.

Keywords: rehabilitation
effect of electrical diaphragmatic stimulation on chronic obstructive pulmonary disease

Conditions: Diaphragm Electrical Activity; COPD (Chronic Obstructive Pulmonary Disease)

Summary: respiratory muscle dysfunction is a common consequence of chronic obstructive pulmonary disease (copd). this technique consists of placing electrodes on the skin at locations near the motor points of the diaphragm, transmitting an intermittent current, and generating action potentials capable of producing muscle contractions

respiratory muscle dysfunction is a common consequence of chronic obstructive pulmonary disease (copd).weakness or fatigue of the diaphragm and accessory muscles of inspiration is widely recognized in patients on mechanical ventilation. there is increasing evidence to show mechanical ventilation itself may adversely affect the diaphragm's structure and function, which has been termed ventilator-induced diaphragmatic dysfunction. however, in patients with more severe copd, the benefits of rehabilitation may be limited. in this context, there are new approaches to pr, such as electrical stimulation, a technique that externally stimulates contractions of peripheral muscles to improve peripheral muscle function in patients with severe copd. this technique consists of placing electrodes on the skin at locations near the motor points of the diaphragm, transmitting an intermittent current, and generating action potentials capable of producing muscle contractions

Eligibility criteria:
inclusion criteria: * age \>18 years. * known cases of copd admitted at respiratory critical care unit with severe acute exacerbation (defined according to gold 2024). exclusion criteria: * body mass index (bmi) \> 35 kg/m2 * post arrest patients * brain death * hemodynamic instability * invasive mv * lung disease other than copd * pregnancy , ascitis. * history of neuromuscular disease at admission * spinal injuries * skin lesions or an open lesion in the regions where the electrodes would be placed * use of pacemakers * patients on maintenance steroid therapy * depletating disease as malignancy 14. patients refusing the procedure

Keywords: chronic obstructive pulmonary disease exacerbation electrical diaphragmatic stimulation
a study to evaluate and compare injections of autologous dermal cells into the balding scalp of subjects with hair loss

Conditions: Androgenetic Alopecia; Male Pattern Baldness; Female Pattern Baldness

Summary: evaluate the ability of ji gami(tm) do to induce hair growth in male and female subjects with hair loss.


Eligibility criteria:
inclusion criteria: * male and female volunteers 18 to 65 years old, inclusive * hair loss consistent with ≥ grade iii-vertex, iv, va, v, and vi, based on norwood-hamilton scale providing there is bridging of hair in the anterior edge of the vertex circle. * have no clinically significant disease or abnormal laboratory results taken at the screening visit. exclusion criteria: * known sensitivity to dmem/f-12 or any component of the study material. * known hypersensitivity to clindamycin hydrochloride, amphotericin b or streptomycin sulfate. * subjects who have used minoxidil, or any oral or topical medication including over the counter and herbal medications for the treatment of hair loss within 6 months of study screening, or finasteride or dutasteride within 12 months of study screening. * a history of drug or alcohol abuse within 1 year of study enrollment. * clinically significant medical or psychiatric illness currently or within 30 days of study screening as determined by the investigator. * any clinically significant abnormal laboratory parameters. * a positive result at screening for human immunodeficiency virus (hiv 1 or 2), hepatitis b or c, htlv i/ii. * dermatologic condition in donation and/or study areas. * prior surgery in the treatment area. * insufficient hair or scarring in the donor area that might impact cell growth. * any disease or condition (medical or surgical) that, in the opinion of the investigator, might compromise hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, or central nervous system function; or any condition that would place the subject at increased risk.

Keywords: androgenetic alopecia male pattern baldness female pattern baldness hair loss baldness
trial of gemcitabine and cisplatin in patients with inoperable biliary tract carcinomas

Conditions: Biliary Tract Carcinoma

Summary: the purpose of this study is to evaluate the efficacy of gemcitabine and cisplatin in korean patients with biliary tract (bile tracts of the gallbladder or liver) cancer.


Eligibility criteria:
inclusion criteria: * histologic or cytologic diagnosis of adenocarcinoma of the gallbladder, intra/extrahepatic bile ducts or papilla of vater with locally advanced or metastatic disease (at study entry) that is not amenable to curative surgical resection or with recurrent disease after prior surgical resection or radiotherapy. * disease status must be measurable disease defined as: bi-dimensionally measurable lesions with clearly defined margins and two perpendicular diameters that are clearly measurable by following: * computerized tomography (ct) or magnetic resonance imaging (mri), with one diameter 2.0 cm or greater and the other diameter 1.0 cm or greater. * palpable lesion, with both diameters 2 cm or greater. disease progressing in areas of prior radiation therapy may be included. * patients must have received no prior chemotherapy for advanced disease. * prior radiotherapy must be completed at least 4 weeks before study enrollment. patients must have recovered from the acute toxic effects of the treatment prior to study enrollment. exclusion criteria: * treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry. * heart failure, angina pectoris or arrhythmia that are poorly controlled in spite of medication or acute myocardial infarction within 6 months preceding study enrollment * severe neurological or mental disorder. * active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy. * poorly controlled diabetes mellitus.
surfacer system to facilitate access in venous occlusions

Conditions: Chronic Venous Thrombosis; Venous Thrombosis Upper Extremity; Venous Thrombosis Upper Extremity Superficial Veins

Summary: prospective, single-arm, multicentre, international registry of the surfacer system for the treatment of patients with limited or diminishing upper body venous access or pathology impeding standard access methods.the purpose of this post-market registry is to assess the standard of care and clinical outcomes of the surfacer system used in clinical routine according to the approved commercial indications.

this is a prospective, single-arm, multicenter registry of the surfacer system for patients with limited or diminishing upper body venous access or pathology impeding standard access methods. the need for long term access and lack of availability of veins has led to the development of the surfacer system, which facilitates reliable and repeatable placement of central venous catheters and restores central venous access. based on european legislation, this registry is considered to be an observational study. no additional diagnostic or monitoring procedures as a result of the inclusion are applied to the patients. available data will be collected in a protected database. up to 30 patients will be enrolled in 5 sites in europe. patients requiring central venous access will be enrolled who meet inclusion and exclusion criteria and for whom the device is indicated.

Eligibility criteria:
inclusion criteria: patients referred for placement of a central venous catheter * patients with limited or diminishing upper body venous access * pathology impeding standard access methods * signed informed consent exclusion criteria: * vulnerable subjects or incapable of giving consent * contraindications to central venous access based on treating physicians opinion or standard of care * occlusion of the right femoral vein * occlusion of the iliac vein * occlusion of the inferior vena * acute thrombosis within a vessel (ivc, brachiocephalic and subclavian)
use of phenylephrine for assessment of mitral regurgitation severity

Conditions: Mitral Regurgitation

Summary: the study proposes to develop a phenylephrine protocol to be used during transesophageal echocardiography, whereby intravenous phenylephrine would be used to increase afterload with the intent to mimic the awake hemodynamic profile and variation that occurs with normal physical activity. the expectation is to see changes in severity of mitral regurgitation (mr) grade with increasing afterload, which in turn can provide more accurate quantification of mr severity to assist in clinical decision making.

routine echocardiography which is used to assess the severity of mitral regurgitation, sometimes underestimates the severity of mitral regurgitation, due to hemodynamic variations that occurs with normal physical activity and under the effect of sedation which is used to perform transesophageal echocardiography. by using phenylephrine during transesophageal echocardiography, the study intends to offset the hemodynamic variation that occurs with sedation and better assess the severity of mitral regurgitation, which would further assist in clinical decision-making regarding treatment. the goal of this study is to compare the severity of mitral regurgitation grade before and after the administration of phenylephrine during transesophageal echocardiography and to demonstrate a 25% increase in severity of mitral regurgitation grade compared to the baseline conditions, following the administration of phenylephrine.

Eligibility criteria:
inclusion criteria: * patients 18 years or older with mr on baseline echocardiographic evaluation who are scheduled to undergo tee for further evaluation of mitral regurgitation. exclusion criteria: * the following patients will be excluded from the study: 1. patients who are not clinically eligible for tee. 2. patients with contraindications to esophageal intubation. 3. patients with hemodynamic instability. 4. patients with acute decompensated heart failure (hf). 5. patients with un-revascularized severe coronary artery disease (triple vessel or left main disease). 6. patients with ongoing unstable angina or ongoing myocardial infarction (mi) 7. patients with significant arrhythmias including atrial fibrillation. 8. patients with uncontrolled hypertension (bp ≥ 150/90 mmhg). 9. patients with preexisting bradycardia (hr \< 50) and heart blocks. 10. patients with severe symptomatic peripheral vascular disease. 11. patients with severe pulmonary hypertension (estimated systolic pulmonary arterial pressure spap ≥ 60mm hg). 12. patients who are at high risk for intracranial bleeding such as patients with previous strokes, transient ischemic attack (tia) and vascular malformations. 13. additionally, patients with mean arterial blood pressure map \> 100 mmhg during tee and those with severe mr, effective regurgitant orifice area (ero \> 39cm2) on baseline tee evaluation will not be given phenylephrine and excluded from the study.
a study to evaluate the impact of 11-month ticagrelor monotherapy following one-month dapt after pci

Conditions: Coronary Artery Disease

Summary: pioneer iv china is sought to investigate the safety and efficacy of 11-month ticagrelor monotherapy following one-month dual antiplatelet therapy (dapt) after ht supreme drug-eluting stent system at 12 months follow-up.

this study is a prospective, multi-center, single-arm objective performance criteria clinical trial in an all-comers patient population (including patients with high bleeding risk, hbr) undergoing pci with unrestrictive use of the ht supreme sirolimus-eluting stent and treated with 11-month ticagrelor monotherapy following one-month dual antiplatelet therapy (dapt) in approximately 285 patients (including 80 coronary heart disease cases entering the oct subgroup). all patients will be (at minimum) contacted via visit at 30 days (±7 days) and at 12 months (±30 days), and by phone contact at 6 months (±14 days), 24 months (±30 days) and 36 months (±45 days) post index procedure to assess clinical status and adverse events. the primary endpoint for this trial is patient-oriented composite endpoint (poce) at 12 months post-procedure.

Eligibility criteria:
inclusion criteria: 1. male or female patient ≥18 years of age; 2. patient has chronic stable angina, acute coronary syndromes or silent ischemia; 3. presence of one or more coronary artery stenoses of ≥50% (by visual assessment) in a native coronary artery (with or without prior stent/other device treatment) or in a saphenous venous or arterial bypass conduit suitable for coronary stent implantation; 4. the vessel should have a reference vessel diameter of at least 2.25 mm by visual assessment (no limitation on the number of treated lesions, vessels, or lesion length); 5. patient has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the ethical committee and is willing to comply with all protocol-required (follow-up) evaluations. exclusion criteria: 1. under 18 years of age; 2. unable to sign written informed consent 3. patient is a woman who is pregnant or nursing 4. known intolerance to cobalt chromium, and medications such as sirolimus, aspirin, heparin, bivalirudin or p2y12 inhibitors; 5. planned major elective surgery requiring discontinuation of dapt within 12 months of procedure; 6. concurrent medical condition with a life expectancy of less than 3 years; 7. currently participating in another trial and not yet at its primary endpoint 8. active pathological bleeding; 9. history of intracranial haemorrhage. oct exclusion criteria 1. left main lesion 2. severe tortuous, calcified or angulated coronary anatomy of the study vessel that in the opinion of the investigator would result in suboptimal imaging or excessive risk of complication from placement of an oct catheter 3. total occlusion or thrombolysis in myocardial infarction(timi) flow 0, prior to wire crossing.

Keywords: healing-targeted supreme one month dapt
heaven criteria: prediction of difficult airway for in- hospital emergency airway management

Conditions: Respiratory Failure

Summary: the heaven criteria were found valid to predict difficult airways during preclinical emergency intubations in a retrospective study. the acronym stands for hypoxemia, extremes of size, anatomic abnormalities, vomit/blood/fluid, exsanguination/anaemia, and neck mobility issues. this is a monocentric prospective observational study to assess the validity of the heaven criteria in the in-hospital setting at a level i adult and pediatric emergency university-based hospital.

emergency intubations are prone to present a difficult airway. a difficult airway can lead to prolonged intubation time and to hypoxemia in situations where oxygenation is not possible that can finally result in hypoxic cardiac arrest and irreversible brain damage caused by hypoxic ischemic encephalopathy. tools to predict difficult airways are rather poor concerning specificity and sensitivity. a score to predict difficult airway developed in the pre-clinical setting are the heaven criteria. the acronym heaven stands for: hypoxemia, extremes of size, anatomic abnormalities, vomit/blood/fluid, exsanguination/anaemia, and neck mobility issues and does not need patients' cooperation. it has been recently validated in the pre-clinical emergency setting and was found to be useful. the study aim is to evaluate if the heaven criteria are suitable to be used to predict difficult airway in in-hospital emergency intubation to finally increase patients' safety during rapid sequence induction (rsi). this prospective observational single-centre study in emergency intubation will consecutively recruit all patients of all ages who need rsi due to their medical condition performed by the staff of the department of anaesthesiology and pain medicine at the bern university hospital. we will record data that are gathered during routine patient care and stored primarily in the departmental anaesthesia information systems. the primary objective is to validate if the heaven criteria, an existing prehospital difficult airway prediction tool, is able to predict airways difficulties during rsi in the clinical in-hospital setting. the secondary objective is, to assess the subcomponent of the heaven criteria and if differences and adaptations are needed comparing it to the prehospital setting.

Eligibility criteria:
inclusion criteria: * all consecutive patients of all ages who need an in-hospital rapid sequence intubation (rsi) performed by the staff of the department of anesthesiology and pain medicine * given general consent or delayed obtained general consent after the procedure * english, german or french speaking patients exclusion criteria: • patients without informed consent

Keywords: emergency medicine intubation, intratracheal anesthesiology rapid sequence induction difficult airway prediction tool